NCT07047508
Real-world Study to Describe the Effectiveness and Safety Outcomes of Jardiance in Chinese Patients With Heart Failure and Preserved Ejection Fraction
Not Yet Recruiting · Not specified · Boehringer Ingelheim · registry updated 2026-09-16
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
The main objective of the study is to describe the effectiveness and safety outcomes among Chinese hospitalized heart failure with preserved ejection fraction (HFpEF) patients initiating Jardiance® in the real-world setting.
Inclusion
- At least 18 years of age
- At least 6 months of data prior to the index date
- Left ventricular ejection fraction (LVEF) \> 40 %
- N-terminal Pro-B-type natriuretic peptide (NT-proBNP) \> 125 pg/mL or brain natriuretic peptide (BNP) ≥ 35 pg/mL
- At least 1 diagnosis of Heart failure with preserved ejection fraction (HFpEF) or Heart failure with mid-range ejection fraction (HFmrEF) or chronic heart failure (CHF) at baseline during the look-back period (on or prior to the index date)
- New users of Jardiance® (initiating Jardiance® on or after March 1st, 2023, and without any record of Jardiance® prescription during the look-back period)
Exclusion
- Patients treated with any other sodium-glucose cotransporter-2 inhibitors (SGLT2i) on the index date or during the look-back period